Back to top
more

Omeros (OMER)

(Real Time Quote from BATS)

$3.30 USD

3.30
1,127,214

-0.87 (-20.86%)

Updated May 16, 2024 03:54 PM ET

After-Market: $3.30 0.00 (0.00%) 4:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 43% (143 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for OMER

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Omeros Corporation [OMER]

Reports for Purchase

Showing records 261 - 280 ( 423 total )

Company: Omeros Corporation

Industry: Medical - Products

Record: 261

05/21/2014

Industry Report

Pages: 47

May and 2014 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 262

05/19/2014

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of May 19

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 263

05/15/2014

Company Report

Pages: 8

Q1 Financials Not Material in Front of Imminent OMIDRIA PDUFA Decision; Reiterate OUTPERFORM and $37 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 264

04/21/2014

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of April 21

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 265

04/11/2014

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of April 14

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 266

04/09/2014

Daily Note

Pages: 46

April and 2014 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 267

03/18/2014

Company Report

Pages: 9

2013 Financials In-Line. Recent Financings Provide Runway Into 2015 and Cover Major 2014 Catalysts. Reiterate OUTPERFORM and Increasing to $37 PT.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 268

02/17/2014

Company Report

Pages: 9

2013 Financials In-Line. Recent Financings Provide Runway Into 2015 and Cover Major 2014 Catalysts. Reiterate OUTPERFORM and Increasing to $37 PT.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 269

02/04/2014

Daily Note

Pages: 52

February and 2014 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 270

02/04/2014

Daily Note

Pages: 52

February and 2014 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 271

02/02/2014

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb. 3

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 272

01/29/2014

Daily Note

Pages: 6

Positive OMS824 Phase 2a Results in Schizophrenia Warrant Further Development in Multiple Neuropsychiatric Disorders; Reiterate OUTPERFORM and $32 FV

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 273

01/03/2014

Industry Report

Pages: 47

January and 2014 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 274

01/03/2014

Industry Report

Pages: 47

January and 2014 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 275

01/03/2014

Industry Report

Pages: 5

LIFE SCIENCES AND HEALTH CARE

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 276

01/03/2014

Daily Note

Pages: 5

LIFE SCIENCES AND HEALTH CARE

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 277

12/16/2013

Company Report

Pages: 9

Potentially Transforming Catalysts Make OMER One of Our Top Picks for 2014; Reiterating OUTPERFORM and $32 FV

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 278

12/08/2013

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 9

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 279

12/02/2013

Daily Note

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 2

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 280

12/02/2013

Industry Report

Pages: 52

December 2013 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party